Biography

Ronen is the Principal Scientist at Hemogenyx Pharmaceuticals in charge of all research operations. His main goal is to advance the research and development projects at Hemogenyx, including the design of new chimeric receptor to utilize various immune cells to target malignant cells or infectious agents, such as SARS-CoV-2, HBV, Ebola, and other viruses. Additionally, after a successful process development and approved IND, Ronen oversee the GMP manufacturing of CAR-T cell therapy for relapsed/refractory acute myeloid leukemia (R/R AML).

Ronen has completed his doctoral studies in the Heart Research Laboratory, Faculty of Medicine at the Technion – Israel Institute of Technology. There he studied inherited cardiomyopathies focusing on the underlying cellular and molecular mechanisms. His research showed electrophysiological and molecular abnormalities in induced pluripotent stem cell-derived cardiomyocytes of PRKAG2-myopathy and DMD patients, which were restored to normal function by means of CRISPR/Cas9 gene editing. Prior to his Ph.D. studies, he graduated summa cum laude from the Technion as a Biotechnology and Food Engineer and received a B.Sc. degree. Ronen has published numerous peer-reviewed papers in the fields of cardiomyocyte electrophysiology, induced pluripotent stem cells, and genome editing; additionally, he has presented his work at several prestigious conferences in the US and Europe.